TOP TEN perturbations for 40007_at (Homo sapiens)

Organism: Homo sapiens
Gene: 40007_at
Selected probe(set): 227346_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 40007_at (227346_at) across 6674 perturbations tested by GENEVESTIGATOR:

zalypsis study 2 / untreated OPM1 cell sample

Relative Expression (log2-ratio):-4.9430056
Number of Samples:2 / 2
Experimental zalypsis study 2
OPM1 multiple myeloma cells treated in vitro with zalypsis (5 nM), a novel marine-derived compound with potent antimyeloma activity. Cells were harvested at the beginning of induction of cell death (15-20% cell death as assessed by Annexin V-FITC staining). ATC code:---
Control untreated OPM1 cell sample
OPM1 multiple myeloma cells untreated.

lung adenocarcinoma study 9 (metastase; lymph node) / lung adenocarcinoma study 9 (metastase; brain)

Relative Expression (log2-ratio):4.568617
Number of Samples:3 / 6
Experimental lung adenocarcinoma study 9 (metastase; lymph node)
Metastatic tumor tissue obtained from the lymph node of patients with primary lung adenocarcinoma.
Control lung adenocarcinoma study 9 (metastase; brain)
Metastatic tumor tissue obtained from the brain of patients with primary lung adenocarcinoma.

Sjogren's syndrome study 2 (pSS) / Sjogren's syndrome study 2 (non-pSS)

Relative Expression (log2-ratio):4.4547625
Number of Samples:7 / 14
Experimental Sjogren's syndrome study 2 (pSS)
Incisional biopsy of one parotid gland of patients who fulfilled the 2002 AECG criteria for primary Sjogren's syndrome (pSS). Patients were at least 21 years old.
Control Sjogren's syndrome study 2 (non-pSS)
Incisional biopsy of one parotid gland of patients with Sicca-syndrome who did not fulfill the 2002 AECG criteria for primary Sjogren's syndrome (non-pSS Sicca). Patients were at least 21 years old.

expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) / expO ovary cancer study 1 (dysgerminoma; metastatic)

Relative Expression (log2-ratio):-4.052884
Number of Samples:2 / 2
Experimental expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic)
Metastatic tumor tissue samples obtained from patients with primary granulosa cell tumor of the ovary.
Control expO ovary cancer study 1 (dysgerminoma; metastatic)
Metastatic tumor tissue samples obtained from patients with primary dysgerminoma of the ovary.

kidney transplantation study 16 (2 week) / normal natural killer cell (CD56+) sample

Relative Expression (log2-ratio):-3.873064
Number of Samples:3 / 3
Experimental kidney transplantation study 16 (2 week)
CD56+ natural killer cell samples derived from kidney transplant patients 2 weeks post-transplantation. Samples were collected 2 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal natural killer cell (CD56+) sample
CD56+ natural killer cell samples derived from healthy control subjects.

Sjogren's syndrome study 2 (pSS) / normal parotid gland tissue

Relative Expression (log2-ratio):3.8484535
Number of Samples:7 / 9
Experimental Sjogren's syndrome study 2 (pSS)
Incisional biopsy of one parotid gland of patients who fulfilled the 2002 AECG criteria for primary Sjogren's syndrome (pSS). Patients were at least 21 years old.
Control normal parotid gland tissue
Samples taken from the dorsal caudal lobe of the parotid gland from control subjects that were at least 21 years old. Samples were harvested during surgery for oral or oropharyngeal squamous cell carcinoma. Histopathologic evaluation of parotid tissue from controls revealed no carcinoma

expO ovary cancer study 1 (serous cystadenocarcinoma, NOS; metastatic) / expO ovary cancer study 1 (dysgerminoma; metastatic)

Relative Expression (log2-ratio):-3.707264
Number of Samples:8 / 2
Experimental expO ovary cancer study 1 (serous cystadenocarcinoma, NOS; metastatic)
Metastatic tumor tissue samples obtained from patients with primary serous cystadenocarcinoma (NOS) of the ovary.
Control expO ovary cancer study 1 (dysgerminoma; metastatic)
Metastatic tumor tissue samples obtained from patients with primary dysgerminoma of the ovary.

inclusion body myositis study 1 / normal biceps tissue

Relative Expression (log2-ratio):3.4582586
Number of Samples:5 / 3
Experimental inclusion body myositis study 1
Biceps femoris biopsy muscle samples from patients with clinical diagnosis of inclusion body myositis (IBM).
Control normal biceps tissue
Biceps femoris biopsy muscle samples from control subjects.

necrotizing myopathy study 1 / inclusion body myositis study 1

Relative Expression (log2-ratio):-3.400567
Number of Samples:3 / 5
Experimental necrotizing myopathy study 1
Biceps femoris biopsy muscle samples from patients with clinical diagnosis of necrotizing myopathy (NM).
Control inclusion body myositis study 1
Biceps femoris biopsy muscle samples from patients with clinical diagnosis of inclusion body myositis (IBM).

inclusion body myositis study 2 / normal quadriceps tissue

Relative Expression (log2-ratio):3.392251
Number of Samples:5 / 2
Experimental inclusion body myositis study 2
Quadriceps femoris biopsy muscle samples from patients with clinical diagnosis of inclusion body myositis (IBM).
Control normal quadriceps tissue
Quadriceps femoris biopsy muscle samples from control subjects.